Skip to main content
SpringerLink
Log in

Resection of the Primary in Unresectable Colorectal Cancer Liver Metastases – Is It Worth?

  • Chapter
  • First Online:
Colorectal Cancer Liver Metastases

  • 905 Accesses

Abstract

Many patients with colorectal liver metastasis cannot be cured of their disease. This is because it has spread widely throughout the liver and is therefore not resectable. In this context, palliative chemotherapy is the main treatment modality. Moreover, in many of these patients, the primary tumor that caused the problem is relatively asymptomatic, and from a clinical perspective, a major problem in dealing with these patients is what to do with the primary cancer. In other words, it is a matter of great debate whether some of these patients benefit from a palliative primary tumor resection once some studies have suggested that resecting the primary cancer can prolong survival and prevent complication arising from the cancer, such as obstruction or bleeding. This review addresses the question of whether surgically removing the primary cancer is beneficial to patients with unresectable colorectal liver metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.

    Article  PubMed  Google Scholar 

  2. Feo L, Polcino M, Nash G. Resection of the primary tumor in stage IV colorectal cancer: when is it necessary? Surg Clin North Am. 2017;97:657–69.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol. 2005;12:637–45.

    Article  PubMed  Google Scholar 

  4. Verhoef C, Wilt J, Burger J, et al. Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer. 2011 Sep;47(Suppl 3):S61–6.

    Article  PubMed  Google Scholar 

  5. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.

    Article  PubMed  CAS  Google Scholar 

  6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  7. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.

    Article  PubMed  CAS  Google Scholar 

  8. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.

    Article  PubMed  CAS  Google Scholar 

  9. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.

    Article  PubMed  CAS  Google Scholar 

  10. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19(11):1829–35. https://doi.org/10.1093/annonc/mdn398. Epub 2008 Jul 28; Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379−84.

    Article  PubMed  CAS  Google Scholar 

  11. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52(4):568–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6(7):651–7.

    Article  PubMed  CAS  Google Scholar 

  13. Mahteme H, Pahlman L, Glimelius B, Graf W. Prognosis after surgery in patients with incurable rectal cancer: a population based study. Br J Surg. 1996;83(8):1116–20.

    Article  PubMed  CAS  Google Scholar 

  14. Crane CH, Janjan NA, Abbruzzese JL, et al. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys. 2001;49(1):107–16.

    Article  PubMed  CAS  Google Scholar 

  15. Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33(10):846–50.

    Article  PubMed  CAS  Google Scholar 

  16. Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer − is it worthwhile? Dis Colon Rectum. 1997;40(1):11–4.

    Article  PubMed  CAS  Google Scholar 

  17. Konyalian VR, Rosing DK, Haukoos JS, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Color Dis. 2007;9(5):430–7.

    Article  CAS  Google Scholar 

  18. Beham A, Rentsch M, Pullmann K, et al. Survival benefit in patients after palliative resection vs non-resection colon cancer surgery. World J Gastroenterol. 2006;12(41):6634–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Costi R, Mazzeo A, Di Mauro D, et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14(9):2567–76.

    Article  PubMed  Google Scholar 

  20. Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Color Dis. 2004;19(3):197–202.

    Article  Google Scholar 

  21. Mik M, Dziki L, Galbfach P, et al. Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? Color Dis. 2010;12(7 Online):e61–7.

    CAS  Google Scholar 

  22. Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89(4):211–7.

    Article  PubMed  Google Scholar 

  23. Yun HR, Lee WY, Lee WS, et al. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient’s status. Int J Color Dis. 2007;22(11):1301–10.

    Article  Google Scholar 

  24. Frago R, Kreisler E, Biondo S, et al. Outcomes in the management of obstructive unresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36(12):1187–94.

    Article  PubMed  CAS  Google Scholar 

  25. Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg. 2010;8(4):305–13.

    Article  PubMed  Google Scholar 

  26. Ruo L, Gougoutas C, Paty PB, et al. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722–8.

    Article  PubMed  Google Scholar 

  27. Kaufman MS, Radhakrishnan N, Roy R, et al. Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study. Color Dis. 2008;10(5):498–502.

    Article  CAS  Google Scholar 

  28. Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with nonresectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28(5):434–7.

    Article  PubMed  Google Scholar 

  29. Benoist S, Pautrat K, Mitry E, et al. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92(9):1155–60.

    Article  PubMed  CAS  Google Scholar 

  30. Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352–8; discussion: 358.

    Article  PubMed  Google Scholar 

  31. Bajwa A, Blunt N, Vyas S, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35(2):164–7.

    Article  PubMed  CAS  Google Scholar 

  32. Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol. 2010;33(1):52–5.

    Article  PubMed  Google Scholar 

  33. Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol. 2009;7:28.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Seo GJ, Park JW, Yoo SB, et al. Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol. 2010;102(1):94–9.

    Article  PubMed  Google Scholar 

  35. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370(9582):135–42.

    Article  PubMed  CAS  Google Scholar 

  36. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–72.

    Article  PubMed  CAS  Google Scholar 

  37. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011 Nov;18(12):3252–60.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination therapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized controlled trial. Lancet. 2007;370:135–42.

    Article  PubMed  CAS  Google Scholar 

  39. Tol J, Koopman M, Rodenburg CJ, et al. A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer: the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19:734–8.

    Article  PubMed  CAS  Google Scholar 

  40. Ahmed S, Leis A, Chandra-Kanthan S, et al. Surgical management of the primary tumor in stage IV colorectal cancer: a confirmatory retrospective cohort study. J Cancer. 2016;7:837–45.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Faron M, Pignon JP, Malka D, et al. Is primary tumor resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomized trials. Eur J Cancer. 2015;51:166–76.

    Article  PubMed  Google Scholar 

  42. Ducreux M, Bouche O, Pignon JP, et al. Randomized trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 trial. Oncology. 2006;70:222–30.

    Article  PubMed  CAS  Google Scholar 

  43. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomized, phase 3 trial. Lancet Oncol. 2011;12:1032–44.

    Article  PubMed  CAS  Google Scholar 

  44. Ducreux M, Adenis A, Mendiboure J, et al. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV1FOLFIRI versus BEV1XELIRI (FNCLCC ACCORD-13/0503). Abstr Annu Meet Am Soc Clin Oncol. 2009;27:4086.

    Google Scholar 

  45. Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128:682–90.

    Article  PubMed  CAS  Google Scholar 

  46. Clancy C, Burke JP, Barry M, et al. A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. 2014;21:3900–8.

    Article  PubMed  Google Scholar 

  47. Tarantino I, Warschkow R, Worni M, et al. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients. A population-based, propensity score-adjusted trend analysis. Ann Surg. 2015;262:112–20.

    Article  PubMed  Google Scholar 

  48. Lam-Boer J, Van der Geest L, Verhoef C, et al. Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: a nationwide population-based propensity-score adjusted study in the Netherlands. Int J Cancer. 2016;139:2082–94.

    Article  PubMed  CAS  Google Scholar 

  49. He WZ, Rong YM, Jiang C, et al. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen. Chin J Cancer. 2016;35(1):58–65.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Kodaz H, Erdogan B, Hacibekiroglu I, et al. Primary tumor resection offers higher survival advantage in KRAS mutant metastatic colorectal cancer patients. Hepatogastroenterology. 2015;62(140):876–9.

    PubMed  Google Scholar 

  51. Dorajoo SR, Tan WJ, Koo SX, et al. A scoring model for predicting survival following primary tumour resection in stage IV colorectal patients with unresectable metastasis. Int J Color Dis. 2016;31(2):235–45.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Abdomino-Pelvic Surgery, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

    Marcus Valadão, Rinaldo Gonçalves & Rodrigo Araújo

  2. Department of Medical Oncology, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

    Roberto de Almeida Gil

Authors
  1. Marcus Valadão
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rinaldo Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rodrigo Araújo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto de Almeida Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Valadão .

Editor information

Editors and Affiliations

  1. National Cancer Institute, Rio de Janeiro, Brazil

    Mauro Monteiro Correia

  2. Banner MD Anderson Cancer Center, Phoenix, AZ, USA

    Michael A. Choti

  3. Virginia Mason Medical Center, Seattle, WA, USA

    Flavio G. Rocha

  4. Center for Advanced Treatment of HBP Diseases, Ageo Central General Hospital, Ageo Shi, Saitama, Japan

    Go Wakabayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Valadão, M., Gonçalves, R., Araújo, R., de Almeida Gil, R. (2020). Resection of the Primary in Unresectable Colorectal Cancer Liver Metastases – Is It Worth?. In: Correia, M., Choti, M., Rocha, F., Wakabayashi, G. (eds) Colorectal Cancer Liver Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-25486-5_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25486-5_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25485-8

  • Online ISBN: 978-3-030-25486-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation